Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

NCT05374590 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ENROLLING_BY_INVITATION

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Myasthenia Gravis
gMG

Interventions

BIOLOGICAL: Efgartigimod IV or Efgartigimod PH20 SC

Sponsor

argenx